Key facts
- It has raised $157.1M; the latest was Later Stage VC ($69.0M) in Feb 2025.
- Notable investors include Oriental Fortune Capital, Co-Stone Capital, Green Pine Capital Partners, Changde Caixin Financial Holding, Zhuhai Gree — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Readline
- ·The full record, as it builds
Funding rounds
No funding rounds for Readline are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Readline
Developer of immobilized enzyme catalytic technology and application intended for green technology. The company provides immobilized enzyme catalytic technology based on biocomputing and AI, green chemistry, genetic engineering, enzyme engineering, cell engineering, fermentation engineering, intelligent automation and quality research to peptides, polysaccharides, and non-natural amino acid product development, enabling businesses in medicine, health products, cosmetics, food, feed and other industries with green product production efficiency and economic benefits.
- Sector
- Materials and Resources
- HQ
- Shenzhen, China
- Founded
- 2017
- Employees
- 400
- Website
- szreadline.com/
- Ownership
- Privately Held (backing)
Readline doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Readline shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Readline in its N-PORT filings yet. We sweep new filings monthly.